Luxbright AB AI Stock Analysis
Want to see SE:LXB full AI Analyst Report?
Luxbright AB (LXB) AI Stock Analysis
Luxbright AB
(Nasdaq OMX AB:LXB)
The score is primarily constrained by chronic unprofitability and deteriorating cash generation. A debt-free balance sheet and revenue growth provide some support, while mixed technical momentum and loss-based valuation keep the overall rating low.
Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 14.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 261.74K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- -0.38
- Revenue Growth
- -13.46%
- EPS Growth
- 4.76%
- Country
- Sweden
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Luxbright AB Business Overview & Revenue Model
Company Description
Luxbright AB (publ), a technology-driven enterprise headquartered in Gothenburg, Sweden, specializes in engineering and marketing X-ray tubes, generators, and comprehensive X-ray systems. Established in 2012, the company's primary focus is on providi...
How the Company Makes Money
Luxbright AB’s revenue model is based on monetizing its X-ray source technology through sales and commercialization of products and related offerings. The primary revenue stream is expected to be direct revenue from delivering X-ray sources and/or in...
Luxbright AB Financial Statement Overview
Summary
Revenue is growing and the company is debt-free, but persistent net losses, negative gross profit, deeply negative operating cash flow, and negative return on equity indicate substantial financial weakness.
Income Statement
25NegativeBalance Sheet
65PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.35M | 11.41M | 9.02M | 854.70K | 811.70K | 729.00K |
| Gross Profit | -38.22M | -21.37M | 8.88M | -2.80M | 189.12K | 1.98M |
| EBITDA | -19.23M | -16.76M | -15.72M | -23.87M | -20.47M | -17.63M |
| Net Income | -21.51M | -19.46M | -17.72M | -25.38M | -21.13M | -18.10M |
Balance Sheet | ||||||
| Total Assets | 32.25M | 39.38M | 42.66M | 40.69M | 31.19M | 23.99M |
| Cash, Cash Equivalents and Short-Term Investments | 362.00K | 5.29M | 12.36M | 14.04M | 7.60M | 7.51M |
| Total Debt | 3.24M | 4.56M | 254.19K | 206.02K | 588.34K | 1.10M |
| Total Liabilities | 8.85M | 12.49M | 8.46M | 7.00M | 3.33M | 3.36M |
| Stockholders Equity | 23.41M | 26.89M | 34.20M | 33.69M | 27.86M | 20.63M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Operating Cash Flow | -20.93M | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Investing Cash Flow | -2.92M | -3.65M | -3.44M | -3.99M | -7.15M | -4.15M |
| Financing Cash Flow | 7.89M | 16.46M | 18.28M | 30.82M | 27.88M | -708.00K |
Luxbright AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 6.10 is below the 20-day moving average (MA) of 6.46, above the 50-day MA of 5.73, and below the 200-day MA of 16.43, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 48.93 is Neutral, neither overbought nor oversold. The STOCH value of 60.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.
Luxbright AB Peers Comparison
Overall Rating
SE:PAX61Neutral
SE:BACTI.B53Neutral
SE:LXB45Neutral
SE:SDOS40Underperform
SE:SPEC38Underperform
SE:SCIB30Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | SEK 1.44B | -286.43 | -1.22% | ― | 34.05% | -144.96% | |
| 53Neutral | SEK 544.93M | 85.56 | 1.93% | ― | -0.51% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | SEK 14.83M | -0.39 | -85.54% | ― | -13.46% | 4.76% | |
| 40Underperform | SEK 31.93M | -3.59 | ― | ― | -19.44% | -475.48% | |
| 38Underperform | SEK 22.68M | -0.12 | -57.15% | ― | ― | 16.02% | |
| 30Underperform | SEK 160.26M | -0.71 | -303.61% | ― | 51.21% | 42.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:LXB | Luxbright AB | 6.10 | -56.69 | -90.28% | |
| SE:PAX | Paxman AB | 62.50 | 1.90 | 3.14% | |
| SE:SCIB | SciBase Holding AB | 11.25 | -8.40 | -42.75% | |
| SE:SPEC | SpectraCure AB | 0.01 | -0.12 | -89.05% | |
| SE:BACTI.B | Bactiguard Holding AB | 15.40 | -0.80 | -4.94% | |
| SE:SDOS | ScandiDos AB | 0.44 | -0.62 | -58.49% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026
